Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience

So Young Huh, Su Hyun Kim, Ki Hoon Kim, Young Nam Kwon, Sung Min Kim, Seung Woo Kim, Ha Young Shin, Yeon Hak Chung, Ju Hong Min, Jungmin So, Young Min Lim, Kwang Kuk Kim, Nam Hee Kim, Tai Seung Nam, Sa Yoon Kang, Jeeyoung Oh, Seong Il Oh, Eunhee Sohn, Ho Jin Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Purpose Fingolimod (FTY) inhibits lymphocyte egress from lymphoid organs to cause lymphopenia, but the clinical implications of FTY-induced lymphopenia are not fully understood. We aimed to determine the frequency and severity of lymphopenia during FTY treatment among Korean patients with multiple sclerosis (MS), and its association with infections. Methods We retrospectively reviewed the medical records of patients with MS treated using FTY from 12 referral centers in South Korea between March 2013 and June 2021. Patients were classified according to their nadir absolute lymphocyte count (ALC) during treatment: grade 1, 800–999/μL; grade 2, 500–799/μL; grade 3, 200–499/μL; and grade 4, <200/μL. Results FTY treatment was administered to 69 patients with a median duration of 18 months (range=1–169 months), with 11 patients being treated for ≥7 years. During FTY treatment, mean ALCs were reduced after the first month (653.0±268.9/μL, mean±standard deviation) (p<0.0001) and remained low during treatment lasting up to 84 months. During follow-up, 41 (59.4%) and 7 (10.1%) patients developed grade-3 and grade-4 lymphopenia, respectively. No significant difference was found in age at FTY initiation, sex, baseline ALC, body mass in-dex, or prior disease-modifying treatment between patients with and without grade-4 lympho-penia. Infections were observed in 11 (15.9%) patients, and the frequencies of patients with and without grade-4 lymphopenia were similar. Conclusions FTY treatment induced grade-4 lymphopenia in 10% of South Korean patients with MS, but did not appear to be associated with an increased infection risk.

Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalJournal of Clinical Neurology (Korea)
Volume18
Issue number6
DOIs
StatePublished - Nov 2022

Keywords

  • fingolimod
  • lymphopenia
  • multiple sclerosis

Fingerprint

Dive into the research topics of 'Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience'. Together they form a unique fingerprint.

Cite this